Amelioration	amelioration	O	O	O	O
of	of	O	O	O	O
bendrofluazide-induced	bendrofluazide-induced	O	O	O	O
hypokalemia	hypokalemia	O	O	OTHERS	I
by	by	O	O	O	O
timolol	timolol	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
beta	beta	O	O	O	O
adrenergic	adrenergic	O	O	O	O
blocking	blocking	O	O	O	O
drug	drug	O	O	O	O
,	,	O	O	O	O
timolol	timolol	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
tended	tended	O	O	O	O
to	to	O	O	O	O
correct	correct	O	O	O	O
the	the	O	O	O	O
hypokalemia	hypokalemia	O	O	OTHERS	I
of	of	O	O	O	O
short-term	short-term	O	O	O	O
bendrofluazide	bendrofluazide	O	O	OTHERS	I
treatment	treatment	O	O	O	O
in	in	O	O	O	O
6	6	O	O	O	O
healthy	healthy	O	O	O	O
male	male	O	O	O	O
subjects	subjects	O	O	O	O
and	and	O	O	O	O
although	although	O	O	O	O
the	the	O	O	O	O
effect	effect	O	O	O	O
was	was	O	O	O	O
small	small	O	O	O	O
it	it	O	O	O	O
was	was	O	O	O	O
significant	significant	O	O	O	O
.	.	O	O	O	O

Timolol	timolol	CHEMICALS	O	OTHERS	I
also	also	O	O	O	O
reduced	reduced	O	O	O	O
the	the	O	O	O	O
rise	rise	O	O	O	O
in	in	O	O	O	O
plasma	plasma	O	O	O	O
aldosterone	aldosterone	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
urine	urine	O	O	O	O
potassium	potassium	CHEMICALS	O	OTHERS	I
excretion	excretion	O	O	O	O
following	following	O	O	O	O
bendrofluazide	bendrofluazide	O	O	OTHERS	I
and	and	O	O	O	O
increased	increased	O	O	O	O
the	the	O	O	O	O
urine	urine	O	O	O	O
sodium/potassium	sodium/potassium	O	O	O	O
ratio	ratio	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
was	was	O	O	O	O
no	no	O	O	O	O
evidence	evidence	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
shift	shift	O	O	O	O
of	of	O	O	O	O
potassium	potassium	CHEMICALS	O	OTHERS	I
from	from	O	O	O	O
the	the	O	O	O	O
intracellular	intracellular	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
extracellular	extracellular	O	O	O	O
space	space	O	O	O	O
.	.	O	O	O	O

